161 related articles for article (PubMed ID: 8946471)
1. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.
Yokoi T; Kosaka Y; Chida M; Chiba K; Nakamura H; Ishizaki T; Kinoshita M; Sato K; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1996 Oct; 6(5):395-401. PubMed ID: 8946471
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.
Yokota H; Tamura S; Furuya H; Kimura S; Watanabe M; Kanazawa I; Kondo I; Gonzalez FJ
Pharmacogenetics; 1993 Oct; 3(5):256-63. PubMed ID: 8287064
[TBL] [Abstract][Full Text] [Related]
5. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.
Evert B; Griese EU; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481
[TBL] [Abstract][Full Text] [Related]
6. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
[TBL] [Abstract][Full Text] [Related]
7. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
8. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype.
Chida M; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T
Pharmacogenetics; 1999 Jun; 9(3):287-93. PubMed ID: 10471060
[TBL] [Abstract][Full Text] [Related]
9. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese].
Yokoi T; Kamataki T
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):5-14. PubMed ID: 9755457
[TBL] [Abstract][Full Text] [Related]
10. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin HV; Meyer UA; Gonzalez FJ
Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820
[TBL] [Abstract][Full Text] [Related]
11. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
12. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
14. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.
Marez D; Legrand M; Sabbagh N; Lo-Guidice JM; Boone P; Broly F
Hum Genet; 1996 May; 97(5):668-70. PubMed ID: 8655150
[TBL] [Abstract][Full Text] [Related]
15. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
18. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 genotype determination in the Danish population.
Brøsen K; Nielsen PN; Brusgaard K; Gram LF; Skjødt K
Eur J Clin Pharmacol; 1994; 47(3):221-5. PubMed ID: 7867674
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
